Patents Examined by Sarvamangala Devi
  • Patent number: 10351452
    Abstract: Compositions for a phage particle are disclosed. The phage particle is non-replicating and includes at least one heterologous nucleic acid sequence that is capable of being expressed in a target bacteria. The expressed heterologous nucleic acid sequence is non-lethal to the target bacteria.
    Type: Grant
    Filed: January 26, 2015
    Date of Patent: July 16, 2019
    Assignee: SynPhaGen LLC
    Inventors: Todd Bernard Parsley, Christian Furlan Freguia
  • Patent number: 10351606
    Abstract: A novel, mutated Salmonella enterica serovar Typhimurium vaccine is generated and imparts protective immunity in vaccinated animals for a range of S. enterica serovars. The vaccine can be attenuated or inactivated, including bacterial ghosts or membrane fractions thereof. Immunogenic compositions are included in the invention and methods of generating an immune response.
    Type: Grant
    Filed: December 7, 2017
    Date of Patent: July 16, 2019
    Assignee: The United States of America, as Represented by the Secretary of Agriculture
    Inventors: Bradley L. Bearson, Shawn M. Bearson
  • Patent number: 10342860
    Abstract: Factor H binding proteins that can elicit antibodies that are bactericidal for at least one strain of N. meningitidis, and methods of use of such proteins, are provided.
    Type: Grant
    Filed: October 24, 2017
    Date of Patent: July 9, 2019
    Assignee: Children's Hospital & Research Center At Oakland
    Inventors: Peter T. Beernink, Dan M. Granoff
  • Patent number: 10334857
    Abstract: A novel Chromobacterium phragmitis sp. nov. strain 113-1 (NRRL B-67133) is described, which has insecticidal activity against insect larvae, in general, and dipteran and lepidopteran insect larvae, in particular. A biocontrol agent containing Chromobacterium phragmitis sp. nov. strain 113-1 (NRRL B-67133) and optionally a carrier are also described. Methods of killing insect larvae and methods of reducing insect populations in an area by applying to the area or an object an effective amount of the biocontrol agent are also described.
    Type: Grant
    Filed: October 10, 2017
    Date of Patent: July 2, 2019
    Assignee: The United States of America, as represented by the Secretary of Agriculture
    Inventors: Michael B. Blackburn, Dawn E. Gundersen-Rindal, Robert R. Farrar, Daniel J. Kuhar, Ashaki D. Mitchell
  • Patent number: 10300122
    Abstract: The present invention relates to Neisseria ORF2086 proteins, crossreactive immunogenic proteins which can be isolated from nesserial strains or prepared recombinantly, including immunogenic portions thereof, biological equivalents thereof, antibodies that immunospecifically bind to the foregoing and nucleic acid sequences encoding each of the foregoing, as well as the use of same in immunogenic compositions that are effective against infection by Neisseria meningitidis serogroup B.
    Type: Grant
    Filed: February 27, 2017
    Date of Patent: May 28, 2019
    Assignee: Wyeth Holdings LLC
    Inventors: Gary W. Zlotnick, Leah Diane Fletcher, John Erwin Farley, Liesel A. Bernfield, Robert J. Zagursky, Benjamin J. Metcalf
  • Patent number: 10301362
    Abstract: A method and composition for eliciting an immune response to group A streptococcal bacteria in a mammal is provided, which includes administering to the mammal an M protein fragment, variant or derivative thereof and a SpyCEP protein or peptide fragment, or an antibody to the SpyCEP protein or fragment to facilitate restoring or enhancing neutrophil activity. Also provided is an immunodominant peptide fragment of SpyCEP.
    Type: Grant
    Filed: April 15, 2015
    Date of Patent: May 28, 2019
    Assignee: Griffith University
    Inventors: Manisha Pandey, Michael Batzloff, Michael Good
  • Patent number: 10300173
    Abstract: The invention relates to compounds, compositions and methods for biofilm disruption and prevention. In particular, the invention relates to pharmaceutical compositions for the disruption of biofilm and prevention of biofilm in patients. The invention also relates to anti-biofouling compositions for the disruption of biofilm and prevention of biofilm on surfaces. The invention also relates to the removal of biological material from surfaces. The compositions of the invention include microbial deoxyribonucleases.
    Type: Grant
    Filed: May 4, 2017
    Date of Patent: May 28, 2019
    Assignee: University of Newcastle Upon Tyne
    Inventors: James Grant Burgess, Michael John Hall, Reindert Nijland
  • Patent number: 10286016
    Abstract: The present invention relates to compositions and methods for preventing and/or treating gonorrhea. In particular, the present invention provides compositions comprising an effective amount of a commensal species of Neisseria (e.g., an effective amount of an extract of a commensal species of Neisseria), wherein such compositions are capable of inhibiting the growth of Neisseria gonorrhoeae.
    Type: Grant
    Filed: September 2, 2015
    Date of Patent: May 14, 2019
    Assignees: ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA, THE HENRY M. JACKSON FOUDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.
    Inventors: Won Jong Kim, Maria Auxilio Rendón-Espinosa, Magdalene Yh So, Maira Goytia, Ann Jerse, Dustin Higashi
  • Patent number: 10272147
    Abstract: An injectable immunogenic composition comprising capsular saccharides from at least two of serogroups A, C, W135 and Y of Neisseria meningitidis, wherein said capsular saccharides are conjugated to carrier protein(s) and/or are oligosaccharides, and wherein (i) the composition comprises <50 ?g meningococcal saccharide per dose, and/or (ii) the composition further comprises an antigen from one or more of: (a) serogroup B N. meningitidis; (b) Haemophilus influenzae type B; and/or (c) Streptococcus pneumoniae. Saccharide antigens in the compositions are generally conjugated to a carrier.
    Type: Grant
    Filed: January 30, 2004
    Date of Patent: April 30, 2019
    Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventor: Paolo Costantino
  • Patent number: 10266817
    Abstract: A botulinum toxin-human epidermal growth factor fusion protein with increased skin cell proliferation and anti-oxidation effect has the amino acid sequence of SEQ ID NO: 2, a gene consisting of E. coli (Escherichia coli) codon-optimized nucleotide sequence of SEQ ID NO: 1 for encoding the botulinum toxin-human epidermal growth factor fusion protein, a recombinant vector including the gene, a host cell transformed with the recombinant vector, and a method for producing a botulinum toxin-human epidermal growth factor fusion protein by transforming a host cell with the recombinant vector, and a cosmetic composition for regenerating skin and improving skin wrinkle including, as an effective component, a botulinum toxin-human epidermal growth factor fusion protein, and as the cosmetic composition has an effect of regenerating skin and improving skin wrinkle, it can be advantageously used in future in the field of cosmetics or cosmetic plastic surgery.
    Type: Grant
    Filed: July 22, 2016
    Date of Patent: April 23, 2019
    Assignees: NEXGEN BIOTECHNOLOGIES, INC.
    Inventors: Sun Kyo Lee, Han Bong Ryu, Seong Ran Lee, Jong Nam Choi, Tae Won Choi, Tae Hyun Kim, Tae Hwa Jeong, Hyeong Il Kwon
  • Patent number: 10266572
    Abstract: Variant factor H binding proteins that can elicit antibodies that are bactericidal for at least one strain of Neisseria meningitidis, compositions comprising such proteins, and methods of use of such proteins, are provided.
    Type: Grant
    Filed: July 22, 2015
    Date of Patent: April 23, 2019
    Assignee: Children's Hospital & Research Center At Oakland
    Inventor: Peter T. Beernink
  • Patent number: 10258688
    Abstract: Adjuvants comprising chitosan cross-linked with an aldehyde or mannosylated chitosan are provided herein. Methods of making the adjuvants and methods of combining or linking the adjuvants with antigens are also provided. The adjuvant-antigen combinations can be used in vaccine formulations and the vaccine formulations can be used in methods to vaccinate animals against the source of the antigen or to enhance the immune response in a subject.
    Type: Grant
    Filed: November 29, 2016
    Date of Patent: April 16, 2019
    Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS
    Inventors: Billy M. Hargis, Neil R. Pumford, Marion Morgan, Srichaitanya Shivaramaiah, Guillermo Tellez-Isaias, Amanda Wolfenden
  • Patent number: 10233433
    Abstract: A formulation comprising an ingestible carrier and an isolated strain of Bifidobacterium longum.
    Type: Grant
    Filed: August 26, 2016
    Date of Patent: March 19, 2019
    Assignees: Alimentary Health Ltd., The Procter & Gamble Company
    Inventors: Jose Carlos Garcia-Garcia, Michael John Janusz, Barry Kiely, Eileen Frances Murphy, Liam O'Mahony
  • Patent number: 10226506
    Abstract: This invention concerns compositions and methods of treating or diagnosing inflammatory disorders and other disorders, as well as compositions and methods of treating HIV.
    Type: Grant
    Filed: December 6, 2017
    Date of Patent: March 12, 2019
    Assignees: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY, ACTINOBAC BIOMED, INC.
    Inventors: Scott C. Kachlany, Benjamin Belinka
  • Patent number: 10213503
    Abstract: Herein we describe construction of a select agent-excluded B. mallei ?tonB ?hcp1 (CLH001) vaccine strain and demonstrate its ability to protect against acute respiratory glanders. Particularly, CLH001 is shown to be attenuated, safe, and effective at protecting against lethal B. mallei challenge. This strain should be useful in vaccines are for use in humans and animals, e.g., equines, in treating or providing immunoprotection against infections elicited by category B, tier 1 pathogens, in particular Burkholderia mallei (Bm) and B. pseudomallei, the causative agents of human glanders and melioidosis, respectively.
    Type: Grant
    Filed: May 18, 2017
    Date of Patent: February 26, 2019
    Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventor: Alfredo G. Torres
  • Patent number: 10206958
    Abstract: Disclosed herein are compositions that have substantially purified Christensenellaceae bacteria, and uses of these compositions to alter the microbiome of an individual. The addition of Christensenellaceae bacteria, such as Christensenella, to the microbiome of an individual can treat or prevent weight gain, reduce body weight, inhibit fat accumulation, reduce excess adiposity, and reduce a high body mass index (BMI), and can also treat or prevent conditions correlating with excess weight and fat and a high BMI, such as insulin sensitivity, metabolic syndrome, excess adiposity, and diabetes.
    Type: Grant
    Filed: April 23, 2015
    Date of Patent: February 19, 2019
    Assignee: CORNELL UNIVERSITY
    Inventors: Ruth E. Ley, Julia Goodrich, Jillian Waters
  • Patent number: 10196453
    Abstract: Clostridium difficile is the most common hospital acquired pathogen in the United States, and infection is in many cases fatal. Toxins A and B are its major virulence factors, but increasingly a third toxin may be present, known as C. difficile transferase (CDT). An ADP-ribosyltransferase that causes actin cytoskeletal disruption, CDT is typically produced by the major, hypervirulent strains and has been associated with more severe disease. It is disclosed herein that CDT enhances the virulence of two PCR-ribotype 027 strains in mice. The toxin induces pathogenic host inflammation via a novel Toll-like Receptor 2 (TLR2) dependent pathway, resulting in the suppression of a protective host eosinophilic response. Finally, it is disclosed that restoration of TLR2 deficient eosinophils is sufficient for protection from a strain producing CDT. These findings offer an explanation for the enhanced virulence of CDT-expressing C.
    Type: Grant
    Filed: May 17, 2017
    Date of Patent: February 5, 2019
    Assignee: University of Virginia Patent Foundation
    Inventors: Carrie Adeline Cowardin, William A. Petri, Jr.
  • Patent number: 10195259
    Abstract: Provided herein are compositions comprising substantially non-viable Gram-negative bacterial organisms that have a substantial reduction in endotoxin activity and/or pyrogenicity and methods for treating a cancer using the same. Also provided are methods for treating cancer provided herein, comprising administering to a mammal diagnosed with cancer, substantially non-viable Gram-negative bacteria having a substantial reduction in endotoxin activity and/or pyrogenicity, in an amount sufficient to inhibit growth or metastasis of the cancer. An additional method is provided comprising administering viable or non-viable Gram-negative bacterial organisms that have a genetic defect that results in a substantial loss of lipopolysaccharide within the outer membrane of the bacteria. Further provided are methods for reducing endotoxin activity and/or pyrogenicity in Gram-negative bacteria comprising treatment with polymyxin and glutaraldehyde.
    Type: Grant
    Filed: December 23, 2013
    Date of Patent: February 5, 2019
    Assignee: Decoy Biosystems, Inc.
    Inventor: Michael J. Newman
  • Patent number: 10188715
    Abstract: The present invention relates to a composition comprising Brachyspira hyodysenteriae bacteria, particularly in the field of immunization against swine dysentery. The composition of the invention may comprise bacteria from at least two genetically diverse strains of B. hyodysenteriae. The composition of the invention may also comprise bacteria of a strain deposited at the Collection Nationale de Cultures de Microorganismes (CNCM), Institut Pasteur, on Mar. 14, 2013, with registration number CNCM I-4720. The invention relates also to the composition of the invention for use as a vaccine, preferably a universal vaccine against swine dysentery caused by B. hyodysenteriae.
    Type: Grant
    Filed: December 29, 2017
    Date of Patent: January 29, 2019
    Assignees: AQUILON CYL SOCIEDAD LIMITADA, UNIVERSIDAD DE LEÓN
    Inventors: Pedro Miguel Rubio Nistal, Ana Maria Carvajal Urueña, Marta García Díez
  • Patent number: 10149889
    Abstract: The invention relates to pharmaceutical compositions comprising leukotoxin, including methods to treat lymphoma, and methods to diagnose lymphoma. The lymphoma includes lymphoma cells expressing activated LFA-1, and the leukotoxin binds to the activated LFA-1 on the lymphoma cells and destroys the lymphoma cells by apoptosis or necrosis, thereby treating said lymphoma.
    Type: Grant
    Filed: March 28, 2016
    Date of Patent: December 11, 2018
    Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventor: Scott Kachlany